
Synthetic biology opens new avenues for developing and discovering natural products of therapeutic value in a sustainable manner. Traditional ‘grind and find’ bioactivity-guided fractionation approaches tend to pose challenges including rediscovery of known compounds, low production yields, and lack of ability to generate analogs for drug development. This perspective covers key examples of using synthetic biology strategies to overcome such barriers through generating difficult-to-source compounds, exploring the chemical space, harnessing next-generation hosts for improved synthesis, and modularizing the biosynthetic pathway for efficient manipulation and optimization. We highlight key examples of synthetic biology applied to develop therapeutically relevant natural products from the main classes of natural products: terpenes, polyketides, nonribosomal peptides, and ribosomally synthesized and posttranslationally synthesized peptides. Taken together, these new approaches provide access to complex and difficult-to-source natural products to develop next-generation medicines.
Nitrogenase activity depends on exceptionally complex metallocofactors, whose biosynthesis requires the coordinated action of diverse proteins for their assembly, maturation, and trafficking. Their formation proceeds from simple [Fe–S] clusters to increasingly complex metalloclusters, namely the P-cluster, NifB-co, and the active-site cofactors FeMo-co, FeV-co, and FeFe-co. Over the past two years, studies have identified new steps in early [Fe–S] cluster delivery, provided insights into P-cluster maturation, refined models of NifB-co synthesis, and reshaped our understanding of FeMo-co maturation. Research on alternative nitrogenases has further revealed differences in P-cluster maturation between nitrogenase isoforms and post-translational mechanisms that preserve cofactor specificity. Despite this progress, important challenges remain, including the experimental capture of transient intermediates, unresolved late steps of FeMo-co biosynthesis, and gaps in our understanding of cofactor maturation in the alternative nitrogenases. This review provides an overview of the current state of nitrogenase cofactor biosynthesis, highlighting key unresolved questions in the field.
The total synthesis of genomes is a bottom-up bioengineering approach which empowers synthetic biologists to investigate complex biological hypotheses and reprogramme cells with novel functions. A successful genome synthesis requires (i) an informed design, (ii) a tractable approach to replace genomic with synthetic DNA, and (iii) a troubleshooting strategy for design flaws. While enabled by the advent of in vitro DNA synthesis and kilobase-scale in vivo DNA assembly approaches, this review highlights recent advances in megabase-scale assembly technologies as well as the nucleotide-resolution mapping of genotype-phenotype relationships. Collectively, these synthetic genomic techniques have enabled the completion of rewritten prokaryotic genomes and eukaryotic chromosomes. Furthermore, we discuss next-generation innovations in ML-driven genome design applied toward ongoing genome synthesis projects, which combined with expedited assembly techniques promise to increase the functional sequence space of redesigned organisms.
G-quadruplexes (G4s) are higher-order structures formed from repetitive guanine-rich genomic sequences. They have several roles in human cancer, including mediating genomic instability. G4s are over-represented in the cancer genome, notably in oncogene promoter sequences, where they are involved in transcriptional regulation. Appropriate low-molecular weight compounds can selectively bind to these G4s and inhibit transcription of these genes. This has been exploited in the design of G4 ligands as putative anticancer agents. At least three such structurally distinct compounds have demonstrated significant antitumour activity in animal models: CX-5461, QN-302 and (E,E)-bisantrene (a recent resurrection and modification of an older anticancer drug). Their favourable pharmacological profiles have enabled them to advance to clinical trial assessments, which are surveyed in this article.